$23.03
+0.01(0.04%)
Mkt Cap $1.6B
$12.66
$25.46
52-Week Range
At a Glance
AI-generatedPulse Biosciences, Inc.
8-K
Pulse Biosciences, Inc. issued a press release on March 12, 2026, announcing the first enrollment of patients in an investigator-initiated clinical study. This event was disclosed under Item 8.01 Other Events with Exhibit 99.1.$1.6B
Market Cap
$353.1K
Revenue
-$73M
Net Income
Employees75
Fundamentals
How The Business Makes Money
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Industry Medical - Instruments & Supplies
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001625101
ISINUS74587B1017
CUSIP74587B101
Phone510 906 4600
Address3957 Point Eden Way, Miami, CA, 94545, US
SEC EDGAR